Stay Up
to Date
Stay Up
to Date
Breaking News,
Updates, & More
Breaking News,
Updates, & More
Click Here to
Subscribe
Click Here to
Subscribe

Biomarker Data in Melanoma Presented at ASCO 2018 Are Largely Extensions of Previous Studies Rather Than New Discoveries

Videos - Video, ASCO
Sanjiv Agarwala, MD
Dr Sanjiv Agarwala argues that much of the biomarker data in melanoma presented at ASCO 2018 are around the value of PD-L1 testing; however, even PD-L1–negative melanoma patients seem to respond to anti–PD-1 therapy, although some studies suggest PD-L1–negative patients may be better candidates for combination immunotherapy.
Related Items
What is Minimal Residual Disease (MRD) Negativity?
Leslie Lauersdorf, ARNP
Videos published on December 6, 2019 in ASH 2019 MM, Multiple Myeloma, Video
Multiple Myeloma as a Chronic Disease
Leslie Lauersdorf, ARNP
Videos published on December 6, 2019 in ASH 2019 MM, Multiple Myeloma, Video
Triplets versus Quads
Leslie Lauersdorf, ARNP
Videos published on December 6, 2019 in ASH 2019 MM, Multiple Myeloma, Video
CAR T-Cell Data in Multiple Myeloma
Leslie Lauersdorf, ARNP
Videos published on December 6, 2019 in ASH 2019 MM, Multiple Myeloma, Video
Latest Developments in Multiple Myeloma
Leslie Lauersdorf, ARNP
Videos published on December 6, 2019 in ASH 2019 MM, Multiple Myeloma, Video
Studies Show ACA Reduces Disparities and Increases Access to Earlier Diagnosis and Treatment
Phoebe Starr
TON - August 2019, Vol 12, No 4 published on August 6, 2019 in ASCO
Working Together to Find the New Standard of Care
Andrey Antov, PhD, MBA
Videos published on September 6, 2018 in Video
Opportunities Are Abundant for Navigators in the Field of Genetics and Genomics
Andrey Antov, PhD, MBA
Videos published on September 6, 2018 in Video
Healthcare Team's Relationship to the Patient
Andrey Antov, PhD, MBA
Videos published on September 6, 2018 in Video
The Navigator's Role in Genetic Testing
Andrey Antov, PhD, MBA
Videos published on September 6, 2018 in Video
Last modified: July 25, 2018